Phio Pharmaceuticals Corp.
NASDAQTotal Valuation
Phio Pharmaceuticals Corp. carries a market capitalization of 10.09M, placing it among publicly traded companies globally. Its enterprise value stands at -1.15M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 10.09M |
| Enterprise Value | -1.15M |
Share Statistics
Phio Pharmaceuticals Corp. currently has 11.62M shares outstanding.
| Shares Outstanding | 11.62M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | 0.94 |
| P/TBV Ratio | 0.94 |
| P/FCF Ratio | -0.80 |
| P/OCF Ratio | -0.80 |
Financial Position
Phio Pharmaceuticals Corp. maintains a current ratio of 8.39, meaning it holds 8.4x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 8.39 |
| Quick Ratio | 7.62 |
| Debt / Equity | N/A |
| Debt / EBITDA | N/A |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | -113.71 |
| Return on Assets (ROA) | -100.78 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Phio Pharmaceuticals Corp.'s stock has declined approximately -59.77315% over the past 52 weeks. The 50-day moving average sits at 1.04, while the 200-day moving average is 1.10.
| Beta (5Y) | N/A |
| 52-Week Price Change | -59.77315% |
| 50-Day Moving Average | 1.04 |
| 200-Day Moving Average | 1.10 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -13.47M, while operating income came in at -13.47M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -13.47M |
| Pretax Income | -12.90M |
| Net Income | -12.90M |
| EBITDA | -13.47M |
| EBIT | -13.47M |
| Earnings Per Share (EPS) | -1.35 |
Balance Sheet
Total book value stands at 12.60M, with working capital of 12.59M providing operational flexibility.
| Cash & Cash Equivalents | 13.00M |
| Total Debt | N/A |
| Net Debt | -13.00M |
| Equity (Book Value) | 12.60M |
| Book Value Per Share | 1.08 |
| Working Capital | 12.59M |
Cash Flow
Phio Pharmaceuticals Corp. produced -12.20M in operating cash flow over the past twelve months. After subtracting -7,000.00 in capital expenditures, free cash flow totaled -12.21M - equivalent to -1.28 per share.
| Operating Cash Flow | -12.20M |
| Capital Expenditures | -7,000.00 |
| Free Cash Flow | -12.21M |
| FCF Per Share | -1.28 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -121.75 |
| FCF Yield | -124.96 |
Stock Splits
Phio Pharmaceuticals Corp.'s most recent stock split took place on July 5, 2024 with a 9:1 split ratio.
| Last Split Date | 7/5/2024 |
| Split Ratio | 9:1 |
Scores
Phio Pharmaceuticals Corp. posts an Altman Z-Score of -13.85, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -13.85 |